Another study showed that the newly identified ephrin B1/ErbB/PTPN13 signaling pathway [71] is implicated in the resistance to a monoclonal antibody against ERBB1 (cetuximab) in HNSCC. Here, PTPN13 is linked to head and neck squamous cell carcinoma.